The American Journal of Surgery
Volume 196, Issue 4 , Pages 519-522, October 2008

Impact of neoadjuvant chemotherapy on rate of tissue expander/implant loss and progression to successful breast reconstruction following mastectomy

  • Jonathan Mitchem, M.D.

      Affiliations

    • Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA
  • ,
  • Dave Herrmann

      Affiliations

    • B.S. Rush University Medical School, Chicago, Ill, USA
  • ,
  • Julie A. Margenthaler, M.D.

      Affiliations

    • Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA
    • Alvin J. Siteman Cancer Center, St. Louis MO, USA
  • ,
  • Rebecca L. Aft, M.D., Ph.D.

      Affiliations

    • Department of Surgery, Washington University School of Medicine, St. Louis, MO, USA
    • Alvin J. Siteman Cancer Center, St. Louis MO, USA
    • John Cochran Veterans Hospital, St. Louis, MO, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-314-747-0063; fax: +1-314-454-5509

Received 17 April 2008; received in revised form 27 May 2008

Abstract 

Purpose

We examined the frequency and causes of tissue expander (TE) and permanent implant (PI) reconstruction failure in patients undergoing neoadjuvant chemotherapy.

Methods and materials

Charts were reviewed from 120 patients with clinical stage II/III breast cancer enrolled between 2004 and 2007 into a prospective clinical trial of neoadjuvant chemotherapy. Patient demographics, tobacco use, radiation treatment, and data relating to the loss of TE, as well as progression to PI and PI loss, were collected.

Results

Of 120 patients, 61 underwent 75 mastectomies. Twenty-six patients had 34 TEs placed at the time of mastectomy. Eleven (32%) TEs required removal prior to definitive reconstruction. Fourteen (41%) TEs successfully progressed to PI exchange. Four of the PIs required removal. TE loss occurred most frequently due to infection and extrusion. Radiation, smoking history, or elevated body mass index (BMI) did not significantly affect reconstruction loss.

Conclusion

Thirty-eight percent of immediate TEs or PI placements at the time of mastectomy failed to progress to definitive reconstruction in patients receiving neoadjuvant therapy, suggesting that reconstruction with TEs or PI reconstruction should be used cautiously in this patient population.

Keywords: Breast cancer, Implant/expander, Neoadjuvant chemotherapy

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported in part by grants from Novartis Pharmaceutical Corp. East Hanover, NJ and Pfizer, Inc., Peapack, NJ.

PII: S0002-9610(08)00476-5

doi:10.1016/j.amjsurg.2008.06.016

The American Journal of Surgery
Volume 196, Issue 4 , Pages 519-522, October 2008